Use of bamboo juice and particle composites thereof in medicines or daily chemical products for promoting antibody secretion and / or increasing immune factors

Abstract

A use of bamboo juice and particle composites thereof in medicines or daily chemical products for promoting antibody secretion and / or increasing immune factors. The present invention has the advantages of effectively prompting the secretion of IgA antibodies in oral mucosa and respiratory mucosa, and increasing innate immune-related cytokines in blood.

Description

Application of bamboo sap and its particle complex in medicines or daily chemicals for promoting antibody secretion and / or increasing immune factors Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to the application of bamboo sap and its particle complex in medicines or daily chemicals for promoting antibody secretion and / or increasing immune factors. Background Art

[0002] Viruses like influenza and COVID-19 change their antigenicity every year, circulating as mutants. If the viral strain used in vaccine production matches the antigenicity of the circulating strain, vaccine-induced IgG antibodies can be expected to be effective in protecting against the virus. However, if the antigenicity of the viral strain used in vaccine production differs from that of the circulating strain, vaccine-induced IgG antibodies cannot be expected to be effective in protecting against the virus. Vaccine-activated IgG antibodies are normally present in the blood and can prevent severe illness caused by the virus. Since the respiratory mucosa is the first point of entry for viruses, strengthening the natural immunity of the respiratory mucosa is necessary to prevent viral infection and transmission.

[0003] Secretory immunoglobulin A (secretory IgA) is the primary effector of mucosal immunity and the primary antibody for early prevention of viral invasion. It can agglutinate pathogens, interfere with pathogen movement, neutralize pathogen toxins, and inhibit pathogen adhesion to the respiratory mucosa, thereby preventing further spread of pathogens into the circulatory system. More importantly, secretory IgA antibodies have effective cross-protective capabilities against viral variants.

[0004] Compared to the acquired immune system activated by vaccines, the body's natural immune system is the most effective at resisting viral and bacterial invasions immediately. The immune function of the natural immune system is carried out by a large number of cells, including granulocytes such as eosinophils, neutrophils, and basophils, monocytic cells such as macrophages and dendritic cells, and lymphocytes such as natural killer cells (NK cells) and ILCs.

[0005] Summary of the Invention

[0006] In order to promote the secretion of mucosal IgA antibodies and increase immune-related factors in the blood, the present invention provides the use of bamboo sap and its particle complex in medicines or daily chemicals that promote antibody secretion and / or increase immune factors.

[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0008] In a first aspect, the present invention provides the use of bamboo sap in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0009] In a third aspect, the present invention provides the use of bamboo sap in the preparation of medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0010] In the first aspect or the third aspect,

[0011] Preferably, the bamboo liquid is an aqueous solution containing bamboo extract.

[0012] Preferably, the medicine or daily chemical product is liquid or solid.

[0013] More preferably, the medicine or daily chemical product is any one of a coating preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

[0014] In a second aspect, the present invention provides the use of the bamboo liquid particle complex in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0015] In a fourth aspect, the present invention provides the use of the bamboo liquid particle complex in the preparation of medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0016] In the second aspect or the fourth aspect,

[0017] Preferably, the bamboo sap particle composite is a particle composite formed by bamboo sap and carbonated apatite particles.

[0018] Further preferably, the bamboo liquid particle complex is applied in liquid or solid form to a medicine or daily chemical product that promotes IgA antibody secretion and / or increases natural immunity-related factors; the medicine or daily chemical product is liquid or solid.

[0019] Further preferably, the bamboo liquid particle complex is applied in the form of a solution or suspension to medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0020] More preferably, the medicine or daily chemical product is any one of a coating preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

[0021] In a fifth aspect, the present invention provides a method for promoting IgA antibody secretion and / or increasing natural immunity-related factors, comprising administering an effective amount of the above-mentioned bamboo sap or the above-mentioned bamboo sap particle complex to a subject in need.

[0022] In the present invention, the innate immunity-related factors include IL-2, IL-8, IL-17A, IL-1b, IL-12p70, and IL-6.

[0023] In a preferred embodiment of the present invention, the first to fifth aspects mentioned above prevent or treat bacterial or viral infections by promoting the secretion of IgA antibodies or increasing natural immune-related factors.

[0024] Optionally, the viral infection disease is selected from: coronavirus infection disease (optionally SARS coronavirus infection disease, MERS coronavirus infection disease or new coronavirus infection disease), influenza A, B or C virus infection disease, influenza virus infection disease, hand, foot and mouth disease, measles, mumps, rubella, herpes virus infection disease (optionally herpes simplex virus infection disease, varicella zoster virus infection disease, Epstein-Barr virus infection disease, cytomegalovirus infection disease, human herpes virus type 6, type 7 or type 8 infection disease), respiratory syncytial virus infection disease, African swine fever, swine fever, avian influenza, human papillomavirus infection disease, norovirus infection disease, rotavirus infection disease, AIDS, Ebola virus infection disease, epidemic encephalitis B virus infection disease, dengue virus infection disease, yellow fever virus infection disease, smallpox virus infection disease, human adenovirus infection disease, parvovirus infection disease, and Kabovirus infection disease.

[0025] Optionally, the bacterial infection disease is selected from: Staphylococcus aureus infection disease, Streptococcus pneumoniae infection disease, Streptococcus pyogenes infection disease, Escherichia coli infection disease, influenza bacillus infection disease, Neisseria meningitidis infection disease, Streptococcus viridans infection disease, Candida albicans infection disease, Neisseria gonorrhoeae infection disease, Chlamydia trachomatis infection disease, Trichomonas pseudonecrotica infection disease, and Trichomonas vaginalis infection disease.

[0026] The beneficial technical effects of the present invention are:

[0027] Applying the bamboo sap and bamboo sap particle complex of the present application to medicines or daily chemical products can effectively promote the secretion of IgA antibodies in the oral mucosa and respiratory mucosa, and / or increase natural immune-related cytokines in the blood. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] FIG1 is a diagram showing the experimental process of mouse mucosal secretory IgA in an experimental example of the present invention;

[0029] FIG2 is a statistical diagram of the evaluation of secretory IgA levels in the oral mucosa and respiratory mucosa on Day 10 in an experimental example of the present invention;

[0030] FIG3 is a statistical diagram of cytokines activated in the blood after spraying 5% bamboo liquid on the oral cavity and nasal cavity of a human body in an actual application example of the present invention;

[0031] FIG4 is a statistical diagram of cytokines activated in the blood after the bamboo liquid particle complex is sprayed into the oral cavity and nasal cavity of a human body in an actual application example of the present invention. DETAILED DESCRIPTION

[0032] The technical solutions in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application; it is obvious that the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0033] Example

[0034] In a first aspect, the present invention provides the use of bamboo sap in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0035] Preferably, the bamboo liquid is an aqueous solution containing bamboo extract.

[0036] More preferably, the content of the bamboo extract is at least 5% by mass.

[0037] Among them, as the content of bamboo extract gradually increases, the effect of bamboo juice in promoting the secretion of IgA antibodies and / or increasing natural immune-related factors becomes better.

[0038] Preferably, the medicine or daily chemical product is liquid or solid.

[0039] More preferably, the medicine or daily chemical product is any one of a coating preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

[0040] In a second aspect, the present invention provides the use of the bamboo liquid particle complex in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0041] Preferably, the bamboo sap particle composite is a particle composite formed by bamboo sap and carbonated apatite particles.

[0042] Further preferably, the bamboo liquid particle complex is applied in liquid or solid form to a medicine or daily chemical product that promotes IgA antibody secretion and / or increases natural immunity-related factors; the medicine or daily chemical product is liquid or solid.

[0043] Further preferably, the bamboo liquid particle complex is applied in the form of a solution or suspension to medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

[0044] More preferably, the medicine or daily chemical product is any one of a coating preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

[0045] Among them, IgA antibodies are mucosal secretory immunoglobulin A. Secretory IgA is the main effector of mucosal immunity and the main antibody for early prevention of viral invasion. It can agglutinate pathogens, interfere with pathogen movement, neutralize pathogen toxins, and inhibit pathogen adhesion to the respiratory mucosa, thereby preventing further spread of pathogens to the circulatory system. More importantly, secretory IgA antibodies have effective cross-protection capabilities against viral variants.

[0046] Among them, natural immunity-related factors are cytokines in the blood that are related to natural immunity. The immune function of the natural immune system is undertaken by a large number of cells, including granulocytes such as eosinophils, neutrophils and basophils, single cells such as macrophages and dendritic cells, and lymphocytes such as Natural killer cells (NK cells) and ILCs.

[0047] Application Examples

[0048] The application of bamboo sap in pharmaceuticals or daily chemicals that promote IgA antibody secretion and / or increase natural immune-related factors is described. The bamboo sap is an aqueous solution containing bamboo extract, wherein the bamboo extract content is 5% by mass. The bamboo extract can be prepared by any of the following methods:

[0049] First, crush bamboo and dry it as needed, then dry distill the bamboo under reduced pressure to collect distillate. The reduced pressure is 100 mmHg or less, preferably 10 to 60 mmHg, and more preferably 15 to 45 mmHg. During the reduced pressure dry distillation, the distillation temperature of the dry distillation product depends on the degree of reduced pressure, which is low when the degree of reduced pressure is high and high when the degree of reduced pressure is low. For example, when the reduced pressure dry distillation is carried out at 20 mmHg, the distillation temperature of the dry distillation product is 180 to 200°C.

[0050] Second, the crushed bamboo is supplied to a vacuum dry distillation device and vacuum dry distilled at a temperature of about 200° C. and a pressure of about 20 mmHg, and the distillate is diluted with ethanol.

[0051] The simple refining method for crude bamboo vinegar is primarily based on a natural settling method. This method involves placing the crude bamboo vinegar in a container and allowing it to stand for a period of time, allowing it to separate naturally into layers. The upper layer is a light-colored, clear bamboo vinegar, while the lower layer is a dark brown bamboo tar. Alternatively, organic solvents such as benzene or chlorinated alum can be mixed with the bamboo vinegar in varying proportions, stirred, and allowed to stand for separation into two layers. The two layers are then separated, and the solution is removed, the solvent removed by distillation, and recovered. Other simple refining methods are also currently being used, such as adsorption refining using charcoal, activated carbon, or other substances. These methods involve mixing charcoal, bamboo charcoal, activated carbon, or other substances with the crude bamboo vinegar in a specific proportion, stirring, allowing the mixture to stand, and filtering.

[0052] The invention relates to an application of a bamboo sap particle complex in medicines or daily chemicals for promoting IgA antibody secretion and / or increasing natural immunity-related factors, wherein the bamboo sap particle complex comprises bamboo sap and carbonated apatite particles, and the bamboo sap and carbonated apatite particles form a particle complex, wherein the relative contents of the bamboo sap and carbonated apatite particles are 3.25% and 96.75% by mass.

[0053] A method for preparing the above-mentioned bamboo liquid particle composite comprises the following steps:

[0054] S1. Prepare 100 mL of an aqueous solution containing a mixture of bamboo sap and inorganic ions, wherein the bamboo sap is a 5% by mass aqueous solution containing a bamboo extract, and add 440 mM NaHCO3, 9 mM NaH2PO4, and 58 mM CaCl2;

[0055] S2. After stirring at 20° C. for 3 minutes, the mixture was centrifuged at 4000 rpm for 3 minutes. The resulting precipitate was the bamboo sap particle complex.

[0056] The bamboo extract can be selected from any one of bamboo charcoal ash extract, bamboo ethanol soaking solution, bamboo vinegar solution, bamboo leaf boiled water solution or a combination of several of them.

[0057] As some embodiments, the bamboo extract preparation method is selected from the following:

[0058] First, crush bamboo and dry it as needed, then dry distill the bamboo under reduced pressure to collect distillate. The reduced pressure is 100 mmHg or less, preferably 10 to 60 mmHg, and more preferably 15 to 45 mmHg. During the reduced pressure dry distillation, the distillation temperature of the dry distillation product depends on the degree of reduced pressure, which is low when the degree of reduced pressure is high and high when the degree of reduced pressure is low. For example, when the reduced pressure dry distillation is carried out at 20 mmHg, the distillation temperature of the dry distillation product is 180 to 200°C.

[0059] Second, the crushed bamboo is supplied to a vacuum dry distillation device and vacuum dry distilled at a temperature of about 200° C. and a pressure of about 20 mmHg, and the distillate is diluted with ethanol.

[0060] The simple refining method for crude bamboo vinegar is primarily based on a natural settling method. This method involves placing the crude bamboo vinegar in a container and allowing it to stand for a period of time, allowing it to separate naturally into layers. The upper layer is a light-colored, clear bamboo vinegar, while the lower layer is a dark brown bamboo tar. Alternatively, organic solvents such as benzene or chlorinated alum can be mixed with the bamboo vinegar in varying proportions, stirred, and allowed to stand for separation into two layers. The two layers are then separated, and the solution is removed, the solvent removed by distillation, and recovered. Other simple refining methods are also currently being used, such as adsorption refining using charcoal, activated carbon, or other substances. These methods involve mixing charcoal, bamboo charcoal, activated carbon, or other substances with the crude bamboo vinegar in a specific proportion, stirring, allowing the mixture to stand, and filtering.

[0061] The above-mentioned medicines or daily chemicals exist in the form of liquid preparations, spray preparations, suspensions, paste preparations, and foam preparations. Adding the bamboo liquid particle complex of the present application to the medicines or daily chemicals can effectively promote the secretion of mucosal IgA antibodies and increase the neutralization of natural immune-related cytokines in the blood.

[0062] In an optional embodiment of the present invention, the method for preparing the bamboo liquid comprises: crushing bamboo, optionally drying the bamboo, dry distilling the bamboo under reduced pressure, and collecting the distillate.

[0063] Optionally, the reduced pressure condition for the dry distillation is below 100 mmHg, and may be 10 to 60 mmHg, 15 to 45 mmHg, or 20 mmHg.

[0064] Optionally, the dry distillation temperature is 180-200°C, and optionally, the dry distillation temperature is 200°C.

[0065] Optionally, the bamboo liquid production method further comprises: a step of further distilling the distillate and / or a step of further performing reduced pressure filtration on the distillate.

[0066] Optionally, the bamboo liquid production method further comprises: further diluting the distillate with ethanol.

[0067] Experimental example:

[0068] Experimental mice: C57BL / 6 male mice, 7 weeks old.

[0069] Experimental environment: temperature 20-26℃, humidity 40%-70%.

[0070] Experimental groups: The experiment was divided into 4 groups, with 4 mice in each group.

[0071] 1) 5% bamboo liquid group, containing an aqueous solution of bamboo extract, the bamboo liquid content is expressed in mass percentage.

[0072] 2) Bamboo sap particle complex group, obtained by dissolving the precipitate obtained in step S2 of the above application example in 50 mL of distilled water.

[0073] 3) Carbonate apatite group: 440 mM NaHCO3, 9 mM NaH2PO4, and 58 mM CaCl2 were added to water to prepare a total of 100 mL of solution for spraying.

[0074] 4) 0.2% bamboo fluid group, containing an aqueous solution of bamboo extract, with the bamboo fluid content being expressed in percentage by mass.

[0075] Experimental process:

[0076] The animals were adapted to feeding one week in advance.

[0077] The experimental process of mouse mucosal secretory IgA is shown in Figure 1:

[0078] Day 0: The spray medicine is administered orally and nasally, twice a day, 2 sprays in the mouth, 1 spray in the left nasal cavity, and 1 spray in the right nasal cavity each time.

[0079] Day 10: All mice in each group were killed, and oral, nasal and alveolar lavage fluids were collected for ELISA to detect IgA content.

[0080] Experimental results and analysis:

[0081] Figure 2 shows the assessment of secretory IgA levels in the oral and respiratory mucosa on Day 10. Compared with the 0.2% bamboo sap and apatite groups, the 5% bamboo sap and bamboo sap particle complex treatment groups significantly increased mucosal IgA antibody secretion. Statistical values ​​are expressed as mean ± standard error. One-way ANOVA and Tukey's multiple comparisons test were used for statistical evaluation, with P < 0.05 considered significant.

[0082] Practical application examples

[0083] Effects of 5% bamboo sap on human blood cytokines.

[0084] Subject: 39-year-old healthy male

[0085] Experimental procedure: Day 0-7 oral and nasal spray 5% bamboo liquid, 3 times a day, each time give 2 sprays to the oral cavity, 1 spray to the left nasal cavity, and 1 spray to the right nasal cavity.

[0086] Venous blood test: blood draws on Day 0 (before spray), 4, 7, 11, 20

[0087] Detection method: flow cytometry

[0088] Detection items: IL-2, IL-8, IL-17A, IL-1b, IL-12p70, IL-6.

[0089] As shown in FIG3 , spraying 5% bamboo liquid into the oral cavity and nasal cavity of a human body activated blood cytokines IL-2, IL-8, IL-17A, IL-1b, IL-12p70, and IL-6.

[0090] Effects of bamboo liquid particle complex on human blood cytokines.

[0091] Subject: 39-year-old healthy male

[0092] Experimental procedure: Day 0-7 oral and nasal spray of bamboo liquid particle complex, 3 times a day, each time giving 2 sprays to the oral cavity, 1 spray to the left nasal cavity, and 1 spray to the right nasal cavity.

[0093] Venous blood test: blood draws on Day 0 (before spray), 4, 7, 11, 20

[0094] Detection method: flow cytometry

[0095] Detection items: IL-2, IL-8, IL-17A, IL-1b, IL-12p70, IL-6.

[0096] As shown in Figure 4, the bamboo liquid particle complex was sprayed on the human body, oral cavity and nasal cavity to activate the blood cytokines IL-2, IL-8, IL-17A, IL-1b, IL-12p70, and IL-6.

[0097] in:

[0098] IL-2, in clinical medicine, refers to interleukin-2, an immunomodulator. Its primary biological function is to stimulate T cell proliferation, increasing the proliferation and killing activity of cytotoxic T cells, natural killer cells, and lymphokine-activated killer cells. It also promotes the secretion of antibodies and interferon by lymphocytes, exerting antiviral, anti-tumor, and immune-enhancing effects.

[0099] Common clinical uses include: 1. The treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, and lung cancer; the management of malignant pleural effusions and ascites; the cultivation of lymphokine-activated killer cells; and the treatment of pain associated with post-herpetic pain. 2. It can also be used to treat cancer patients after surgery, radiotherapy, and chemotherapy, enhancing immune function. 3. It can be used to treat congenital or acquired immunodeficiency, improving cellular immunity and resistance to infection; balancing immune defenses; and treating allergic diseases caused by hypersensitivity reactions, such as allergic rhinitis, allergic asthma, and allergic dermatoses. 4. It can be used to treat various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, and Sjögren's syndrome. 5. It has a significant therapeutic effect on certain viral, bacillary, and intracellular parasitic infections, such as hepatitis B, HPV infection, tuberculosis, and Candida albicans infection.

[0100] L-8 is a chemotactic cytokine. Its main biological function is to attract and activate neutrophils, promote the lysosomal enzyme activity and phagocytosis of neutrophils, and also has a certain chemotactic effect on basophils and T cells. After contact with IL-8, neutrophils undergo morphological changes, migrate to the reaction site in a directed manner and release a series of active products. These effects can lead to local inflammatory reactions in the body, achieving the purpose of killing bacteria and damaging cells.

[0101] IL-17 cytokines effectively recruit monocytes and neutrophils to sites of inflammation by increasing the production of chemokines in tissues. When extracellular pathogens invade the immune system, IL-17, as a pro-inflammatory cytokine, responds and destroys the pathogens.

[0102] IL-1 also plays an important role in the activation of immune cells. It can act on macrophages and monocytes, inducing them to produce toxic activity against bacteria and viruses.

[0103] The main biological effects of IL-6 include:

[0104] 1. Promote B cell proliferation and antibody production: IL-6 can directly act on B cells, promote their proliferation and differentiation, and stimulate the production of antibodies, especially IgA and IgG.

[0105] 2. Activate T cells: IL-6 can increase the activity of T cells, promote their proliferation and activation, especially Th2 and Th17 cells.

[0106] 3. Others: IL-6 can also activate mast cells, NK cells, etc.

[0107] IL-6 plays an important role in infectious diseases and tumors.

[0108] IL-12p70 is a crucial cytokine in cell-mediated immunity. Its primary immunoregulatory function is to induce early helper T cells to differentiate into Th1 cells and promote their development and proliferation. Helper T cells are essential for cell-mediated immune responses and antibody production by B lymphocytes and can be divided into two subpopulations: Th1 and Th2. The former produces IL-2, IL-3, IFN-γ, lymphotoxin, and granulocyte-macrophage colony-stimulating factor, participating in cellular immunity. The latter, on the other hand, produces cytokines such as IL-4, IL-5, IL-10, and IL-13, assisting B cells in antibody production and participating in humoral immunity. Certain pathogens can only be effectively inhibited by either Th1 or Th2 cells.

[0109] IL-12P70 can promote the proliferation and cytotoxicity of T cells and NK cells. These properties of IL-12P70 suggest its potential value as an immunomodulatory factor in the treatment of malignant tumors.

[0110] From the above, it can be seen that the bamboo sap and bamboo sap particle complex of the present application can effectively promote the secretion of IgA antibodies in the oral mucosa and respiratory mucosa, increase the neutralization of natural immunity-related cytokines in the blood, and apply them to medicines or daily chemicals, which can also effectively promote the secretion of IgA antibodies in the oral mucosa and respiratory mucosa, and increase the neutralization of natural immunity-related cytokines in the blood.

[0111] The embodiments of this specific implementation method are all preferred embodiments of the present invention and are not intended to limit the scope of protection of the present invention. The above embodiments can be used in combination with each other. Therefore, any equivalent changes made based on the structure, shape, and principle of the present invention should be included in the scope of protection of the present invention.

Claims

1. Application of bamboo juice in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

2. The use according to claim 1, characterized in that: Bamboo extract is a water solution containing bamboo extract.

3. The use according to claim 1, characterized in that: Medicines or daily chemicals are liquid or solid.

4. The use according to claim 3, characterized in that: The medicine or daily chemical product is any one of a liquid preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

5. Application of bamboo liquid particle complex in drugs or daily chemicals that promote IgA antibody secretion and / or increase natural immunity-related factors.

6. The use according to claim 5, characterized in that: The bamboo sap particle composite is a particle composite formed by bamboo sap and carbonate apatite particles.

7. The use according to claim 6, characterized in that: The bamboo liquid particle complex is applied in liquid or solid form to medicines or daily chemicals that promote IgA antibody secretion and / or increase natural immunity-related factors; the medicines or daily chemicals are liquid or solid.

8. The use according to claim 7, characterized in that: The bamboo liquid particle complex is applied in the form of solution or suspension in medicines or daily chemicals that promote the secretion of IgA antibodies and / or increase natural immunity-related factors.

9. The use according to claim 7, characterized in that: The medicine or daily chemical product is any one of a liquid preparation, a spray preparation, a suspension, a paste preparation, and a foam preparation.

10. The use according to any one of claims 1 to 9, characterized in that: Prevent or treat bacterial or viral infections by promoting IgA antibody secretion and / or increasing natural immune-related factors. Optionally, the viral infection disease is selected from: coronavirus infection disease (optionally SARS coronavirus infection disease, MERS coronavirus infection disease or new coronavirus infection disease), influenza A, B or C virus infection disease, influenza virus infection disease, hand, foot and mouth disease, measles Rash, mumps, rubella, herpes virus infection (optionally herpes simplex virus infection, varicella zoster virus infection, Epstein-Barr virus infection, cytomegalovirus infection, human herpesvirus type 6, 7 or 8 infection), respiratory syncytial virus infection, African swine fever, swine fever, avian influenza, human papillomavirus infection, norovirus infection, rotavirus infection, AIDS, Ebola virus infection, epidemic encephalitis B virus infection, dengue virus infection, yellow fever virus infection, smallpox virus infection, human adenovirus infection, parvovirus infection, and Kabovirus infection. Optionally, the bacterial infection disease is selected from: Staphylococcus aureus infection disease, Streptococcus pneumoniae infection disease, Streptococcus pyogenes infection disease, Escherichia coli infection disease, Haemophilus influenzae infection disease, Neisseria meningitidis infection disease, Streptococcus viridans infection disease, Candida albicans infection disease, Neisseria gonorrhoeae infection disease, Chlamydia trachomatis infection disease, Mycobacterium pseudonecrosis infection disease, and Trichomonas vaginalis infection disease.

11. The use according to any one of claims 1 to 10, characterized in that: The innate immunity-related factors include IL-2, IL-8, IL-17A, IL-1b, IL-12p70, and IL-6.

Images